Blog
RSS FeedPosted by Michael Wonder on 14 Oct 2017
EMA responds to BMJ article questioning benefits of recent cancer drug approvals
13 October 2017 - As more cancer drugs are approved and prices continue to rise, questions have circulated on whether ...
Posted by Michael Wonder on 11 Oct 2017
The future of drug pricing: value over volume
11 October 2017 - Doctors and hospitals are increasingly being paid not for the quantity of care they provide, but ...
Posted by Michael Wonder on 09 Oct 2017
Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
9 October 2017 - Healthcare systems depend on the availability of new antibiotics. ...
Posted by Michael Wonder on 05 Oct 2017
Cancer patients given new drugs that won’t help them
5 October 2017 - Most new cancer drugs are given to patients without any evidence that they extend or improve ...
Posted by Michael Wonder on 04 Oct 2017
Novartis seeks outcomes-based pricing in Japan for cancer drug
5 October 2017 - Swiss pharma's effort could spark broad changes in nation's pricing system. ...
Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...
Posted by Michael Wonder on 13 Sep 2017
Drug companies tie costs to outcomes
12 September 2017 - But early signs show little evidence that the plans lower prices. ...
Posted by Michael Wonder on 09 Sep 2017
Should value frameworks take a ‘societal perspective’?
6 September 2017 - In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness ...
Posted by Michael Wonder on 09 Sep 2017
Can a new value framework help ease friction over orphan drug prices?
7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...
Posted by Michael Wonder on 04 Sep 2017
Statistical and clinical significance
4 September 2017 - In published research, a statistically significant result is often wrongly interpreted as representing a clinically important ...
Posted by Michael Wonder on 28 Aug 2017
How to design the cost-effectiveness appraisal process of new health care technologies to maximise population health: a conceptual framework
22 August 2017 - This paper presents a conceptual framework to analyse the design of the cost-effectiveness appraisal process of new ...
Posted by Michael Wonder on 24 Aug 2017
PCSK9 inhibitors and the choice between innovation, efficiency, and affordability
22 August 2017 - Cardiovascular medicine is struggling with the new proprotein convertase subtilisin/kexin type 9 inhibitor drugs for lowering low-density ...
Posted by Michael Wonder on 24 Aug 2017
Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit?
23 August 2017 - Whether the ASCO Value Framework and the European Society for Medical Oncology Magnitude of Clinical Benefit Scale ...
Posted by Michael Wonder on 24 Aug 2017
Using discrete choice experiments to inform the benefit-risk assessment of medicines: are we ready yet?
23 August 2017 - There is emerging interest in the use of discrete choice experiments as a means of quantifying the ...
Posted by Michael Wonder on 21 Aug 2017
Amgen and Humana partner for improved health outcomes and efficiency
17 August 2017 - Partnership to target multiple serious diseases using real world data studies. ...